MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Sanofi

Закрыт

54.58 1.19

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

53.9

Макс.

55.68

Ключевые показатели

By Trading Economics

Доход

-2.3B

499M

Продажи

-6.5B

7.6B

P/E

Средняя по отрасли

23.205

63.778

Прибыль на акцию

0.682

Дивидендная доходность

3.67

Рентабельность продаж

6.539

Сотрудники

82,878

EBITDA

-3.7B

563M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+20.02% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.67%

2.39%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.5B

136B

Предыдущая цена открытия

53.39

Предыдущая цена закрытия

54.58

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Sanofi График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

20 мар. 2025 г., 06:43 UTC

Приобретения, слияния, поглощения

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

3 февр. 2025 г., 13:19 UTC

Приобретения, слияния, поглощения

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

3 февр. 2025 г., 09:31 UTC

Приобретения, слияния, поглощения

Correction to L'Oreal article

3 февр. 2025 г., 07:09 UTC

Приобретения, слияния, поглощения

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

30 янв. 2025 г., 11:09 UTC

Отчет

Correction to Sanofi Article

30 янв. 2025 г., 06:47 UTC

Отчет

Sanofi Issues $5.2 Billion Share Buyback; Expects Sales, Core Earnings Growth

2 апр. 2025 г., 09:27 UTC

Популярные акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

20 мар. 2025 г., 06:05 UTC

Приобретения, слияния, поглощения

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 мар. 2025 г., 06:05 UTC

Приобретения, слияния, поглощения

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 мар. 2025 г., 06:04 UTC

Приобретения, слияния, поглощения

Sanofi to Pay $600M Upfront

20 мар. 2025 г., 06:02 UTC

Приобретения, слияния, поглощения

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 мар. 2025 г., 06:00 UTC

Приобретения, слияния, поглощения

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

19 февр. 2025 г., 06:35 UTC

Приобретения, слияния, поглощения

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 февр. 2025 г., 06:34 UTC

Приобретения, слияния, поглощения

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 февр. 2025 г., 06:34 UTC

Приобретения, слияния, поглощения

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 февр. 2025 г., 06:33 UTC

Приобретения, слияния, поглощения

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 февр. 2025 г., 06:33 UTC

Приобретения, слияния, поглощения

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 февр. 2025 г., 06:33 UTC

Приобретения, слияния, поглощения

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 февр. 2025 г., 06:32 UTC

Приобретения, слияния, поглощения

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 февр. 2025 г., 06:31 UTC

Приобретения, слияния, поглощения

Sanofi, CD&R Sign Opella Share Purchase Agreement

3 февр. 2025 г., 06:37 UTC

Приобретения, слияния, поглощения

Sanofi Says Transaction Is Part of Its Share Buyback Program

3 февр. 2025 г., 06:35 UTC

Приобретения, слияния, поглощения

L'Oreal: Sale Should Be Finalized in Coming Days

3 февр. 2025 г., 06:35 UTC

Приобретения, слияния, поглощения

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

3 февр. 2025 г., 06:34 UTC

Приобретения, слияния, поглощения

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

3 февр. 2025 г., 06:33 UTC

Приобретения, слияния, поглощения

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

3 февр. 2025 г., 06:32 UTC

Приобретения, слияния, поглощения

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

3 февр. 2025 г., 06:31 UTC

Приобретения, слияния, поглощения

L'Oreal to Sell Sanofi Stake for EUR3B

3 февр. 2025 г., 06:31 UTC

Приобретения, слияния, поглощения

L'Oreal to Sell Sanofi Stake Back to Sanofi

30 янв. 2025 г., 10:47 UTC

Обсуждения рынка
Отчет

Sanofi's Buyback and Increased R&D Spending Are Positive -- Market Talk

30 янв. 2025 г., 10:31 UTC

Обсуждения рынка
Отчет

Sanofi's Lung Drug Beyfortus Sales Beat Stands Out Among 4Q Results -- Market Talk

Сравнение c конкурентами

Изменение цены

Sanofi Прогноз

Целевая цена

By TipRanks

20.02% рост

Прогноз на 12 месяцев

Средняя 64.75 USD  20.02%

Максимум 67 USD

Минимум 63 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Sanofi на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

3

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

N/A / 55.4Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Strong Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.